Brief: Pharming Provides Update On EMA Review Of Leniolisib

Pharming

16/02/2023 07:15

Feb 16 (Reuters) - Pharming Group NV  PHAR.AS :
    * COMMITTEE FOR HUMAN MEDICINAL PRODUCTS (CHMP)HAS DECIDED
TO
SHIFT ITS ASSESSMENT OF MARKETING AUTHORISATION APPLICATION
(MAA) FOR LENIOLISIB TO A STANDARD REVIEW TIMETABLE
    * EXPECTS THAT CHMP WILL ISSUE ITS OPINION ON LENIOLISIB MAA
IN 2H
2023

Source text for Eikon:  ID:nPre2YGCha 
Further company coverage:  PHAR.AS 
 (Gdansk Newsroom)
 ((gdansk.newsroom@thomsonreuters.com;))